SNOA vs SSKN vs DERM vs SKIN

For growth investors, Sonoma Pharmaceuticals, Inc.

(SNOA) is the stronger pick with 12. 2% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -46.

6%, compared to -99. 2% for Sonoma Pharmaceuticals, Inc. (SNOA). Over 10 years, the gap is even starker: DERM returned -46. 6% versus SNOA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 38β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately -566% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Sonoma Pharmaceuticals, Inc. (SNOA) carries a lower debt/equity ratio of 7% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sonoma Pharmaceuticals, Inc.

(SNOA) is pulling ahead at 12. 2% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, SNOA leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKIN leads at -6. 9% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DERM: 131.

8% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNOA (Healthcare) and SSKN (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.